AJCP / Meeting AbstrActs (16.2%) showed low TSR (<0.50). There was significant inverse association (P = .020) between TSR and tumor grade. Low TSR value was found in 3.5% (3/86) of the non-invasive tumors and 35.7% (5/14) of invasive tumors. A highly significant inverse relation was found between TSR and bladder muscle invasion (P < .001). Conclusions: Low TSR was found to be significantly associated with high-grade tumors and muscle invasion, thus, making this a parameter of poor prognostic value.
Atypical hyperplasia is a nonmalignant but high-risk breast lesion with a four-to five-fold increased risk of breast cancer development and an incidence of 10% in otherwise benign breast biopsies. More recently, it has been shown that among women with atypical hyperplasia, the cumulative incidence of breast cancer approaches 30% at 25-year follow-up. Atypical hyperplasia is either ductal (ADH) or lobular (ALH) type, with growing evidence suggesting that it could be a precursor lesion to ductal carcinoma in situ (DCIS). The management of these biopsies is controversial. The current recommendations are excisional biopsy to rule out DCIS or invasive carcinoma. For this study, "benign biopsies" were defined as those without ductal carcinoma in situ, lobular carcinoma in situ, or invasive carcinoma of any type. This is a single-institution retrospective review of breast core needle biopsies diagnosed as ADH or ALH within a five-year period, from 2010 to 2015. The average patient age at diagnosis was 55 years with a range from 19 to 76 years. There were a total of 2,934 biopsies with 1,764 (60%) classified as "no carcinoma." Of the benign cases, 65 (3.7%) were diagnosed as either ADH or ALH. Excision results were available for 57 cases. Of these cases, the diagnosis was benign in 26 (45.6%), residual atypical hyperplasia in 16 (28%), and upgraded to DCIS, lobular carcinoma in situ (LCIS), and/or invasive carcinoma in 15 (26%). Carcinoma diagnosed on excision was more likely to be in situ (10 cases) than invasive (five cases). Overall, our findings are similar to those found in larger studies and, in the case of atypical hyperplasia, support the current management guidelines.
Evaluation of Post-Transoral Endoscopic Circumferential Resection Esophageal Biopsies With p53 Staining
Christina DiCarlo, MD, Emily Lloyd, CCRC, Juliann Kosovec, MS, Ali Zaidi, MD, Blair Jobe, MD, Jan Silverman, MD; Allegheny Health Network, Pittsburgh, PA Objectives: Transoral endoscopic circumferential resection (TECR) with extracellular matrix (ECM) placement is a procedure unique to our institution that is a less invasive treatment for Barrett esophagus (BE) with high-grade dysplasia (HGD) and early adenocarcinoma (EAC). This endoscopic procedure involves circumferential en bloc removal of the affected mucosa and submucosa with subsequent placement of an ECM to prevent stricture formation and promote healing. The aim of this study is to identify abnormal p53 IHC staining within any residual glandular mucosa within the site of TECR. Methods: Post-TECR/ECM biopsies containing glandular-type mucosa in the resection bed and adjacent esophagus were selected for p53 staining, excluding cases with HGD or EAC. P53 staining was assessed as patchy weak nuclear staining (normal), intense nuclear staining (abnormal) or complete loss of staining (abnormal). p53 staining was correlated to histologic findings of benign glandular mucosa, intestinal metaplasia (IM), and lowgrade dysplasia (LGD), or indefinite for dysplasia (IFD). Results: A total of 21 post-TECR/ECM biopsies were evaluated from five patients. p53 staining was interpreted as follows: 11 normal (52.4%) and 10 abnormal (47.6%). Within the abnormal group, all cases contained complete loss of p53 staining. IM was present in three biopsies (14.2%), and IFD was found in one biopsy (4.8%). Only one of the cases with abnormal p53 staining contained IM, while none had dysplasia. The majority of cases (90%) with abnormal p53 staining correlated to normal/ reactive histology. Likewise, two of three cases with IM and IFD displayed normal p53 staining patterns. Conclusion: IHC staining for p53 may be helpful as an adjunct in the surveillance of TECR patients. We demonstrated that abnormal p53 staining could be found in normal/reactive glandular mucosa. The significance of this finding is uncertain, but may indicate the need for closer follow-up in this unique group of patients. 
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PD-L1 Expression Reveals Significant Association With Squamous Differentiation in Upper Tract Urothelial Carcinoma
University of Pennsylvania, Philadelphia
Introduction: The immune checkpoint pathway is a promising target in cancer immunotherapy. Few studies have examined PD-L1 in upper tract (UT) urothelial carcinoma. In this study, we performed a comprehensive study of the differential expression of PD-L1 in UT tumors in relation to clinicopathologic features.
